5 research outputs found
Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial
Objective: The HOME BP (Home and Online Management and Evaluation of Blood Pressure) trial aimed to test a digital intervention for hypertension management in primary care by combining self-monitoring of blood pressure with guided self-management. Design: Unmasked randomised controlled trial with automated ascertainment of primary endpoint. Setting: 76 general practices in the United Kingdom. Participants: 622 people with treated but poorly controlled hypertension (>140/90 mm Hg) and access to the internet. Interventions: Participants were randomised by using a minimisation algorithm to self-monitoring of blood pressure with a digital intervention (305 participants) or usual care (routine hypertension care, with appointments and drug changes made at the discretion of the general practitioner; 317 participants). The digital intervention provided feedback of blood pressure results to patients and professionals with optional lifestyle advice and motivational support. Target blood pressure for hypertension, diabetes, and people aged 80 or older followed UK national guidelines. Main outcome measures: The primary outcome was the difference in systolic blood pressure (mean of second and third readings) after one year, adjusted for baseline blood pressure, blood pressure target, age, and practice, with multiple imputation for missing values. Results: After one year, data were available from 552 participants (88.6%) with imputation for the remaining 70 participants (11.4%). Mean blood pressure dropped from 151.7/86.4 to 138.4/80.2 mm Hg in the intervention group and from 151.6/85.3 to 141.8/79.8 mm Hg in the usual care group, giving a mean difference in systolic blood pressure of −3.4 mm Hg (95% confidence interval −6.1 to −0.8 mm Hg) and a mean difference in diastolic blood pressure of −0.5 mm Hg (−1.9 to 0.9 mm Hg). Results were comparable in the complete case analysis and adverse effects were similar between groups. Within trial costs showed an incremental cost effectiveness ratio of £11 ($15, €12; 95% confidence interval £6 to £29) per mm Hg reduction. Conclusions: The HOME BP digital intervention for the management of hypertension by using self-monitored blood pressure led to better control of systolic blood pressure after one year than usual care, with low incremental costs. Implementation in primary care will require integration into clinical workflows and consideration of people who are digitally excluded. Trial registration: ISRCTN13790648
Calcitonin receptor family evolution and fishing for function using in silico promoter analysis
In the present study the calcitonin receptor (CTR) sub-family of family B G-protein coupled receptors
(GPCRs) in teleosts is evaluated and put in the context of the families overall evolution from echinodermates
to vertebrates. Echinodermates, hemichordates, cephalochordates and tunicates have a single gene
that encodes a receptor that bears similarity to the vertebrate calcitonin receptor (CTR) and calcitoninlike
receptor (CTR/CLR). In tetrapods one gene encodes the calcitonin receptor (CALCR) and another gene
the calcitonin receptor-like receptor (CALCRL). The evolution of CALCR has been under strong conservative
pressure and a single copy is also found in fishes and high conservation of gene organisation and synteny
exits from teleosts to human. A teleost specific CTR innovation that occurred after their divergence
from holostei is the presence of several HBDs in the N-terminus. CALCRL had a different evolutionary trajectory
from CALCR and although a single gene copy is present in tetrapods the sarcopterygii fish, the coelacanth,
has 1 copy of CALCRL but also a fish specific form CALCRL3. The ray-finned fish, the spotted gar,
has 1 copy of CALCRL and 1 of CALCRL3 but the teleost specific whole genome duplication has resulted in
a CALCRL1 and CALCRL2 in addition to the fish specific CALCRL3. Strong conservation of CALCRL gene
structure exists from human to fish. Promoter analysis in silico reveals that the duplicated CALCRL genes
in the teleosts, zebrafish, takifugu, tetraodon and medaka, have divergent promoters and different putative
co-regulated gene partners suggesting their function is different.We are grateful to Professor Adelino Canário for providing the
sequence of sea bass EST clones. This study was supported by the
European Regional Development Fund (ERDF) COMPETE – Operational
Competitiveness Programme and Portuguese funds through
FCT – Foundation for Science and Technology, under the project
‘‘PEst-C/MAR/LA0015/2013’’ and by FCT PTDC/BIA-BCM//73597/
2010. RM (SFRH/BPD/66742/2009) and FV (SFRH/BPD/73597/
2010) were in receipt of a post-doctoral grant from FCT, Portugal
Recommended from our members
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
TERT-locus single nucleotide polymorphisms (SNPs) and leucocyte telomere measures are reportedly associated with risks of multiple cancers. Using the iCOGs chip, we analysed ~480 TERT-locus SNPs in breast (n=103,991), ovarian (n=39,774) and BRCA1 mutation carrier (11,705) cancer cases and controls. 53,724 participants have leucocyte telomere measures. Most associations cluster into three independent peaks. Peak 1 SNP rs2736108 minor allele associates with longer telomeres (P=5.8×10−7), reduced estrogen receptor negative (ER-negative) (P=1.0×10−8) and BRCA1 mutation carrier (P=1.1×10−5) breast cancer risks, and altered promoter-assay signal. Peak 2 SNP rs7705526 minor allele associates with longer telomeres (P=2.3×10−14), increased low malignant potential ovarian cancer risk (P=1.3×10−15) and increased promoter activity. Peak 3 SNPs rs10069690 and rs2242652 minor alleles increase ER-negative (P=1.2×10−12) and BRCA1 mutation carrier (P=1.6×10−14) breast and invasive ovarian (P=1.3×10−11) cancer risks, but not via altered telomere length. The cancer-risk alleles of rs2242652 and rs10069690 respectively increase silencing and generate a truncated TERT splice-variant
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
<p>TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOG, we analyzed similar to 480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 x 10(-7)), lower risks for estrogen receptor (ER)-negative (P = 1.0 x 10(-8)) and BRCA1 mutation carrier (P = 1.1 x 10(-5)) breast cancers and altered promoter assay signal. The minor allele at the peak 2 SNP rs7705526 associates with longer telomeres (P = 2.3 x 10(-14)), higher risk of low-malignant-potential ovarian cancer (P = 1.3 x 10(-15)) and greater promoter activity. The minor alleles at the peak 3 SNPs rs10069690 and rs2242652 increase ER-negative (P = 1.2 x 10(-12)) and BRCA1 mutation carrier (P = 1.6 x 10-14) breast and invasive ovarian (P = 1.3 x 10(-11)) cancer risks but not via altered telomere length. The cancer risk alleles of rs2242652 and rs10069690, respectively, increase silencing and generate a truncated TERT splice variant.</p>